CIPROMET Ciprofloxacin 500mg Film-Coated Tablet 1's
RXDRUG-DRP-1359-1pc
Discreet Packaging
We recognize that purchasing medications can be a deeply personal matter. To respect your privacy, we ensure that all orders are packaged discreetly, with no indication of the contents on the packaging. This means that even our couriers remain unaware of the package contents.
Furthermore, we uphold strict confidentiality standards. We guarantee that your order information will never be disclosed to any third party. Your trust is paramount to us, and we are committed to safeguarding your privacy at every step of the process. Our dedication to discretion and confidentiality is part of our unwavering commitment to you, our valued customer.
FDA-registered Products
FDA-licensed Pharmacies
Features
Brand
Cipromet
Full Details
Dosage Strength
500mg
Drug Ingredients
- Ciprofloxacin
Drug Packaging
Film-Coated Tablet 1's
Generic Name
Ciprofloxacin Hydrochloride
Dosage Form
Film-Coated Tablet
Registration Number
DRP-1359
Drug Classification
Prescription Drug (RX)
Description
Indications/Uses
Uncomplicated and Complicated Infections caused by Ciprofloxacin Sensitive pathogens.
Infections of the kidneys and/or urinary tract.
Infections of the respiratory tract.
Infections of the abdominal cavity (e.g. Infections of the GI tract or of the biliary tract, peritonitis).
Infectious diarrhea & typhoid fever.
Infections of the genital organs, including adnexitis, gonorrhea, prostatitis.
Infection of the middle ear (otitis media), of the paranasal sinuses (sinusitis) especially if these are caused by gram-negative organisms including Pseudomonas or by gram positive pathogens including Staphylococcus.
Infection of the eyes.
Infections of the bones and joints.
Infections of the skin and soft tissue.
Infections or imminent risk of infection (prophylaxis) in patients whose immune system has been weakened (e.g. patients on immunosuppressants or have neutropenia).
Sepsis: Infections or imminent risk of infection (prophylaxis) in patients whose immune system has been weakened (e.g. patients on immunosuppressants or have neutropenia).
Selective Intestinal decontamination in immunosuppressed patients.
According to in-vitro investigations, the following pathogens can be regarded as sensitiive: E.coli, Shigella, Salmonella, Citrobacter; Klebsiella, Enterobacter, Serratia, Hafnia, Edwardsiella, Proteus (indole-positive and indole-negative), Providencia, Morganella, Yersinia, Vibrio, Aeromonas, Plesiomonas, Pasteurella, Haemophillus, Staphylococcus, Listeria, Corynebacterium, Chlamydia.
The following show varying degrees of sensitivity: Gardnerella, Flavobacterium, Alcalagines, Streptococcus agalatiae, Enterococcus faecalis, Streptococcus pyogenes, Streptococcus pneumonia, Viridans group streptococci, Mycoplasma hominis, Mycobacterium tuberculosis, and Mycobacterium fortuitum. With a few exceptions anaerobes are moderately sensitive e.g. Peptococcus, Peptostreptococcus to resistant e.g., Bacteroides.
Ciprofloxacin is ineffective against Treponema pallidum.
Infections of the kidneys and/or urinary tract.
Infections of the respiratory tract.
Infections of the abdominal cavity (e.g. Infections of the GI tract or of the biliary tract, peritonitis).
Infectious diarrhea & typhoid fever.
Infections of the genital organs, including adnexitis, gonorrhea, prostatitis.
Infection of the middle ear (otitis media), of the paranasal sinuses (sinusitis) especially if these are caused by gram-negative organisms including Pseudomonas or by gram positive pathogens including Staphylococcus.
Infection of the eyes.
Infections of the bones and joints.
Infections of the skin and soft tissue.
Infections or imminent risk of infection (prophylaxis) in patients whose immune system has been weakened (e.g. patients on immunosuppressants or have neutropenia).
Sepsis: Infections or imminent risk of infection (prophylaxis) in patients whose immune system has been weakened (e.g. patients on immunosuppressants or have neutropenia).
Selective Intestinal decontamination in immunosuppressed patients.
According to in-vitro investigations, the following pathogens can be regarded as sensitiive: E.coli, Shigella, Salmonella, Citrobacter; Klebsiella, Enterobacter, Serratia, Hafnia, Edwardsiella, Proteus (indole-positive and indole-negative), Providencia, Morganella, Yersinia, Vibrio, Aeromonas, Plesiomonas, Pasteurella, Haemophillus, Staphylococcus, Listeria, Corynebacterium, Chlamydia.
The following show varying degrees of sensitivity: Gardnerella, Flavobacterium, Alcalagines, Streptococcus agalatiae, Enterococcus faecalis, Streptococcus pyogenes, Streptococcus pneumonia, Viridans group streptococci, Mycoplasma hominis, Mycobacterium tuberculosis, and Mycobacterium fortuitum. With a few exceptions anaerobes are moderately sensitive e.g. Peptococcus, Peptostreptococcus to resistant e.g., Bacteroides.
Ciprofloxacin is ineffective against Treponema pallidum.
Dosage/Direction for Use
Ciprofloxacin (Cipromet) is generally administered in oral doses of 250 mg-500 mg BID for most indications for 5-7 days.
Infections of the kidneys, urinary tract & abdominal cavity: Mild to moderate: 250 mg twice daily. Severe complicated: 500 mg twice daily.
Infections of the respiratory tract, bone & joint, skin & skin structures: Mild to moderate: 500 mg twice daily. Severe complicated: 750 mg twice daily.
Infectious diarrhea & typhoid fever: 500 mg twice daily.
Infections of the middle ear (otitis media), paranasal sinuses (sinusitis): 500 mg twice daily.
Bacterial prostatitis: 500 mg twice daily.
Uncomplicated urethral & cervical gonococcal infections: single 250 mg dose is recommended. Elderly patients should receive a dose as low as possible depending on the severity of their illness and creatinine clearance.
Method of Administration: The tablets are swallowed whole with a small amount of fluid. They can be taken independent of mealtimes, (if the tablet is taken on an empty stomach, the active substance is absorbed more rapidly).
Duration of Treatment: The duration of treatment depends on the severity of the illness and on the clinical and bacteriological course. It is essential to continue therapy for at least 3 days after disappearance of the fever or of the clinical symptoms. Mean duration of treatment: up to 7 days for infections of the kidneys, urinary tract, and abdominal cavity; 1 day for acute uncomplicated gonorrhea and cystitis; over the entire period of neutropenic phase in patients with weakened body defenses; a maximum of 2 months in osteomyelitis; 7 to 14 days in all other infections.
In streptococcal Infections the treatment must last at least 10 days, because of the risk of late complications. Infections caused by Chlamydia should also be treated for a minimum of 10 days. Or as prescribed by the physician.
Infections of the kidneys, urinary tract & abdominal cavity: Mild to moderate: 250 mg twice daily. Severe complicated: 500 mg twice daily.
Infections of the respiratory tract, bone & joint, skin & skin structures: Mild to moderate: 500 mg twice daily. Severe complicated: 750 mg twice daily.
Infectious diarrhea & typhoid fever: 500 mg twice daily.
Infections of the middle ear (otitis media), paranasal sinuses (sinusitis): 500 mg twice daily.
Bacterial prostatitis: 500 mg twice daily.
Uncomplicated urethral & cervical gonococcal infections: single 250 mg dose is recommended. Elderly patients should receive a dose as low as possible depending on the severity of their illness and creatinine clearance.
Method of Administration: The tablets are swallowed whole with a small amount of fluid. They can be taken independent of mealtimes, (if the tablet is taken on an empty stomach, the active substance is absorbed more rapidly).
Duration of Treatment: The duration of treatment depends on the severity of the illness and on the clinical and bacteriological course. It is essential to continue therapy for at least 3 days after disappearance of the fever or of the clinical symptoms. Mean duration of treatment: up to 7 days for infections of the kidneys, urinary tract, and abdominal cavity; 1 day for acute uncomplicated gonorrhea and cystitis; over the entire period of neutropenic phase in patients with weakened body defenses; a maximum of 2 months in osteomyelitis; 7 to 14 days in all other infections.
In streptococcal Infections the treatment must last at least 10 days, because of the risk of late complications. Infections caused by Chlamydia should also be treated for a minimum of 10 days. Or as prescribed by the physician.
Overdosage
In the event of acute, excessive oral overdose, reversible renal toxicity has been reported in some cases. Therefore, apart from routine emergency measures, it is recommended to monitor renal function and to administer Mg or Ca containing antacids, which reduce the absorption of Ciprofloxacin.
Only a small amount of Ciprofloxacin (<10%) is removed from the body after hemodialysis or peritoneal dialysis.
Only a small amount of Ciprofloxacin (<10%) is removed from the body after hemodialysis or peritoneal dialysis.
Please sign in so that we can notify you about a reply